Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (63)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (236)
  2. Center for Hematologic Malignancies (236)
  3. Department of Medicine (236)
  4. Hematologic Malignancies, Division of (236)
  5. Hematology-Oncology Fellows (101)
  6. Lymphoma (47)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (4)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (236)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Worldwide examination of patients with CLL hospitalized for COVID-19
    Meeting Abstract

    Roeker, L. E.; Scarfo, L.; Chatzikonstantinou, T.; Abrisqueta, P.; Eyre, T. A.; Cordoba, R.; Prat, A. M.; Villacampa, G.; Leslie, L. A.; Koropsak, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Lech-Marańda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory Richter's transformation and de novo diffuse large B-cell lymphoma
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Foss, F. M.; Isufi, I.; Kothari, S. K.; Ding, W.; Brander, D. M.; Sitlinger, A.; Rosenthal, A. C.; Leis, J. F.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
    Meeting Abstract

    Mato, A.; Tang, B.; Azmi, S.; Yang, K. R.; Stern, J. C.; Hedrick, E.; Huang, J.; Sharman, J. P.
    Blood (2020)

    Fulltext@MSK | Save
  • Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 Patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the informCLL prospective observational registry
    Meeting Abstract

    Mato, A. R.; Barrientos, J. C.; Sharman, J. P.; Brander, D. M.; Gutierrez, M.; Kadish, K.; Arango-Hisijara, I.; Upasani, S.; Han, J.; Huang, Q.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • COVID-19 impact on lymphoma patients' clinical outcomes - An observational cohort study
    Meeting Abstract

    Ip, A.; Mato, A.; Intrator, J.; Howard, N. P.; Petrillo, A.; Vicioso, R.; Sebti, R.; Cicogna, C.; Magarelli, G.; Leslie, L. A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The Prosid study: Evaluating efficacy and safety of intravenous immunoglobulin (IVIG) 10% in primary infection prophylaxis in patients with chronic lymphocytic leukemia-study design
    Meeting Abstract

    Cornely, O.; Mato, A.; Robak, T.; Mellinghoff, S.; Lavrova, T.
    Blood (2020)

    Fulltext@MSK | Save
  • Improving physician-patient decision making for treatment of chronic lymphocytic leukemia with BTK inhibition
    Meeting Abstract

    Ackbarali, T. A.; Davids, M. S.; Turell, W.; Arnone, M.; Mato, A.; Koffman, B.; Del Nido, E. A.; Jacobson, K.
    Blood (2020)

    Fulltext@MSK | Save
  • Assessment of minimal residual disease (MRD) in chronic lymphocytic leukemia: A review of the data and future directions
    Review

    Mato, A. R.
    Clinical Advances in Hematology & Oncology (2020)

    Fulltext@MSK | Save
  • The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia: Q&A
    Miscellaneous

    Cheson, B. D.; Mato, A. R.
    Clinical Advances in Hematology & Oncology (2020)

    Fulltext@MSK | Save